bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

2
3

Davide F. Robbiani1*,#, Christian Gaebler1*, Frauke Muecksch2*, Julio C. C. Lorenzi1*, Zijun

4

Wang1*, Alice Cho1*, Marianna Agudelo1*, Christopher O. Barnes6*, Anna Gazumyan1*, Shlomo

5

Finkin1*, Thomas Hagglof1*, Thiago Y. Oliveira1*, Charlotte Viant1*, Arlene Hurley4, Hans-

6

Heinrich Hoffmann3, Katrina G. Millard1, Rhonda G. Kost5, Melissa Cipolla1, Kristie Gordon1,

7

Filippo Bianchini1, Spencer T. Chen1, Victor Ramos1, Roshni Patel1, Juan Dizon1, Irina

8

Shimeliovich1, Pilar Mendoza1, Harald Hartweger1, Lilian Nogueira1, Maggi Pack1, Jill Horowitz1,

9

Fabian Schmidt2, Yiska Weisblum2, Eleftherios Michailidis3, Alison W. Ashbrook3, Eric Waltari7,

10

John E. Pak7, Kathryn E. Huey-Tubman6, Nicholas Koranda6, Pauline R. Hoffman6, Anthony P.

11

West, Jr.6, Charles M. Rice3, Theodora Hatziioannou2, Pamela J. Bjorkman6, Paul D. Bieniasz2,8,#,

12

Marina Caskey1,#, Michel C. Nussenzweig1,8,#

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

1

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA
3
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY
10065, USA
4
Hospital Program Direction, The Rockefeller University, New York, NY 10065, USA
5
Hospital Clinical Research Office, The Rockefeller University, New York, NY 10065, USA
6
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena,
CA 91125, USA
7
Chan Zuckerberg Biohub, 499 Illinois Street, San Francisco, CA 94158, USA
8
Howard Hughes Medical Institute
*
Equal contribution
#
Send correspondence to Paul D. Bieniasz: pbieniasz@rockefeller.edu, Marina Caskey:
mcaskey@rockefeller.edu, Michel C. Nussenzweig: nussen@rockefeller.edu, or Davide F.
Robbiani: drobbiani@rockefeller.edu
2

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

28

Abstract

29

During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed

30

hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain

31

(RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that

32

antibodies will be essential for protection. However, little is known about the human

33

antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent

34

individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable

35

half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%,

36

while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-

37

specific memory B cells expressing closely related antibodies in different individuals. Despite

38

low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal

39

inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent

40

plasmas obtained from individuals who recover from COVID-19 do not contain high levels

41

of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent

42

antiviral activity were found in all individuals tested, suggesting that a vaccine designed to

43

elicit such antibodies could be broadly effective.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

44

Between April 1 and May 8, 2020, 157 eligible participants enrolled in the study. Of these, 111

45

(70.7%) were individuals diagnosed with SARS-CoV-2 infection by RT-PCR (cases), and 46

46

(29.3%) were close contacts of individuals diagnosed with SARS-CoV-2 infection (contacts).

47

While inclusion criteria allowed for enrollment of asymptomatic participants, 8 contacts that did

48

not develop symptoms were excluded from further analyses. The 149 cases and contacts were free

49

of symptoms suggestive of COVID-19 for at least 14 days at the time of sample collection.

50

Participant demographics and clinical characteristics are shown in Table 1 and Extended Data

51

Tables 1 and 2. Only one individual who tested positive for SARS-CoV-2 infection by RT-PCR

52

remained asymptomatic. The other 148 participants reported symptoms suggestive of COVID-19

53

with an average onset of approximately 39 days (range 17 to 67 days) before sample collection. In

54

this cohort, symptoms lasted for an average of 12 days (0-35 days), and 11 (7%) of the participants

55

were hospitalized. The most common symptoms were fever (83.9%), fatigue (71.1%), cough

56

(62.4%) and myalgia (61.7%) while baseline comorbidities were infrequent (10.7%) (Table 1 and

57

Extended Data Tables 1 and 2). There were no significant differences in duration or severity (see

58

Methods) of symptoms, or in time from onset of symptoms to sample collection between genders

59

or between cases and contacts. There was no age difference between females and males in our

60

cohort (Extended Data Fig. 1).

61
62

Plasma samples were tested for binding to the SARS-CoV-2 RBD and trimeric spike (S) proteins

63

by ELISA using anti-IgG or -IgM secondary antibodies for detection (Fig. 1, Extended Data Table

64

1 and Extended Data Figs. 2 and 3). Eight independent negative controls and the plasma sample

65

from participant 21 (COV21) were included for normalization of the area under the curve (AUC).

66

Overall, 78% and 70% of the plasma samples tested showed anti-RBD and anti-S IgG AUCs that

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

67

were at least 2 standard deviations above the control (Fig. 1 a, b). In contrast, only 15% and 34%

68

of the plasma samples showed IgM responses to anti-RBD and anti-S that were at least 2 standard

69

deviations above control, respectively (Fig. 1 c, d). There was no positive correlation between anti-

70

RBD or -S IgG or IgM levels and duration of symptoms or the timing of sample collection relative

71

to onset of symptoms (Fig. 1e, and Extended Data Figs. 3 a-c and 3 g-j). On the contrary, as might

72

be expected, anti-RBD IgM titers were negatively correlated with duration of symptoms and the

73

timing of sample collection (Fig. 1e and Extended Data Fig. 3h). Anti-RBD IgG levels were

74

modestly correlated to age, and the severity of symptoms including hospitalization (Fig. 1 f, g and

75

Extended Data Fig. 3k). Interestingly, females had lower anti-RBD and -S IgG titers than males

76

(Fig. 1h, Extended Data Fig. 2f).

77
78

To measure the neutralizing activity in convalescent plasmas we used HIV-1-based virions

79

carrying a nanoluc luciferase reporter that were pseudotyped with the SARS-CoV-2 spike (SARS-

80

CoV-2 pseudovirus, see Methods, Fig. 2 and Extended Data Fig. 4). The overall level of

81

neutralizing activity in the cohort, as measured by the half-maximal neutralizing titer (NT50) was

82

generally low, with 33% undetectable and 79% below 1,000 (Fig. 2 a, b). The geometric mean

83

NT50 was 121 (arithmetic mean = 714), and only 2 individuals reached NT50s above 5,000 (Fig. 2

84

a, b and Extended Data Table 1).

85
86

Notably, levels of anti-RBD- and -S IgG antibodies correlated strongly with NT50 (Fig. 2 c, d).

87

Neutralizing activity also correlated with age, duration of symptoms and symptom severity

88

(Extended Data Fig. 5). Consistent with this observation, hospitalized individuals with longer

89

symptom duration showed slightly higher average levels of neutralizing activity than non-

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

90

hospitalized individuals (p=0.0495, Fig. 2e). Finally, we observed a significant difference in

91

neutralizing activity between males and females (p=0.0031, Fig. 2f). The difference between males

92

and females was consistent with higher anti-RBD and -S IgG titers in males, and could not be

93

attributed to age, severity, timing of sample collection relative to onset of symptoms or duration

94

of symptoms (Fig. 1h, Extended Data Fig. 1 a-d and 2f).

95
96

To determine the nature of the antibodies elicited by SARS-CoV-2 infection we used flow

97

cytometry to isolate individual B lymphocytes with receptors that bound to RBD from the blood

98

of 6 selected individuals including the 2 top and 4 high to intermediate neutralizers (Fig. 3). The

99

frequency of antigen-specific B cells, identified by their ability to bind to both Phycoerythrin (PE)-

100

and AF647-labeled RBD, ranged from 0.07 to 0.005% of all circulating B cells in COVID-19

101

convalescents but they were undetectable in pre-COVID-19 controls (Fig. 3a and Extended Data

102

Fig. 6). We obtained 534 paired IgG heavy and light chain (IGH and IGL) sequences by reverse

103

transcription and subsequent PCR from individual RBD-binding B cells from the 6 convalescent

104

individuals (see Methods and Extended Data Table 3). When compared to the human antibody

105

repertoire, several IGHV and IGLV genes were significantly over-represented (Extended Data Fig.

106

7). The average number of V genes nucleotide mutations for IGH and IGL was 4.2 and 2.8,

107

respectively (Extended Data Fig. 8), which is lower than in antibodies cloned from individuals

108

suffering from chronic infections such as Hepatitis B or HIV-1, and similar to antibodies derived

109

from primary malaria infection or non-antigen-enriched circulating IgG memory cells6-8 (Wang et

110

al, in press, https://www.biorxiv.org/content/10.1101/2020.03.04.976159v1.full). Among other

111

antibody features, IGH CDR3 length was indistinguishable from the reported norm and

112

hydrophobicity was below average (Extended Data Fig. 8)9.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

113
114

As is the case with other human pathogens, there were expanded clones of viral antigen binding B

115

cells in all COVID-19 individuals tested (see Methods and Fig. 3 b,c). Overall, 32.2% of the

116

recovered IGH and IGL sequences were from clonally expanded B cells (range 21.8-57.4% across

117

individuals, Fig. 3b). Antibodies that shared specific combinations of IGHV and IGLV genes in

118

different individuals comprised 14% of all the clonal sequences (colored pie slices in Fig. 3 b,c).

119

Remarkably, the amino acid sequences of some antibodies found in different individuals were

120

nearly identical (Fig. 3 e,d). For example, antibodies expressed by clonally expanded B cells with

121

IGHV1-58/IGKV3-20 and IGHV3-30-3/IGKV1-39 found repeatedly in different individuals had

122

amino acid sequence identities of up to 99% and 92%, respectively (Fig. 3d and Extended Data

123

Table 4). We conclude that the IgG memory response to the SARS-CoV-2 RBD is rich in recurrent

124

and clonally expanded antibody sequences.

125
126

To examine the binding properties of anti-SARS-CoV-2 antibodies, we expressed 84

127

representative antibodies, 56 from clones and 28 from singlets (Extended Data Table 5). ELISA

128

assays showed that 94% (79 out of 84) of the antibodies tested including clonal and unique

129

sequences bound to the SARS-CoV-2 RBD with an average half-maximal effective concentration

130

(EC50) of 6.1 ng/mL (Fig. 4a and Extended Data Fig. 9a). A fraction of those (7 out of 79, or 9%)

131

cross-reacted with the RBD of SARS-CoV with a mean EC50 of 120.1 ng/mL (Extended Data Fig.

132

9b and c). No significant cross-reactivity was noted to the RBDs of MERS, HCoV-OC43, HCoV-

133

229E or HCoV-NL63.

134

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

135

To determine whether the monoclonal antibodies have neutralizing activity, we tested them against

136

the SARS-CoV-2 pseudovirus (Fig. 4 and Extended Data Table 6). Among 79 RBD binding

137

antibodies tested, we found 40 that neutralized SARS-CoV-2 pseudovirus with nanogram per

138

milliliter half-maximal inhibitory concentrations (IC50s) ranging from 3 to 709 (Fig. 4 b,c and e,

139

Extended Data Table 6). A subset of the most potent of these antibodies were also tested against

140

authentic SARS-CoV-2 and neutralized with IC50s of less than 5 ng/ml (Fig. 4 d,e).

141
142

Potent neutralizing antibodies were found in individuals irrespective of their plasma NT50s. For

143

example, C121, C144, and C135 with IC50s of 1.64, 2.55 and 2.98 ng/mL against authentic SARS-

144

CoV-2, respectively, were obtained from individuals COV107, COV47, and COV72 whose

145

plasma NT50 values were of 297, 10,433 and 3,138, respectively (Figs. 2b and 4). Finally, clones

146

of antibodies with shared IGHV and IGLV genes were among the best neutralizers, e.g., antibody

147

C002 composed of IGHV3-30/IGKV1-39 is shared by the 2 donors with the best plasma

148

neutralizing activity (red pie slice in Fig. 3b and Fig. 4). We conclude that even individuals with

149

modest plasma neutralizing activity harbor rare IgG memory B cells that produce potent SARS-

150

CoV-2 neutralizing antibodies.

151
152

To determine whether human anti-SARS-CoV-2 monoclonal antibodies with neutralizing activity

153

can bind to distinct domains on the RBD, we performed bilayer interferometry experiments in

154

which a preformed antibody-RBD immune complex was exposed to a second monoclonal. The

155

antibodies tested comprised 3 groups, all of which differ in their binding properties from CR3022,

156

an antibody that neutralizes SARS-CoV and binds to, but does not neutralize SARS-CoV-210,11.

157

Representatives of each of the 3 groups include: C144 and C101 in Group 1; C121 and C009 in

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

158

Group 2; C135 in Group 3. All of these antibodies can bind after CR3022. Groups 1 and 2 also

159

bind after Group 3, and Groups 1 and 2 differ in that Group 1 can bind after Group 2 but not vice

160

versa (Fig. 4 f-n). We conclude that similar to SARS-CoV, there are multiple distinct neutralizing

161

epitopes on the RBD of SARS-CoV-2.

162
163

To further define the binding characteristics of Groups 1 and 2 antibodies, we imaged SARS-CoV-

164

2 S–Fab complexes by negative stain electron microscopy (nsEM) using C002 (Group 1, an

165

IGHV3-30/IGKV1-39 antibody, which is clonally expanded in 2 donors), C119 and C121 (both in

166

Group 2) Fabs (Fig. 4 f-r and Extended Data Fig. 10). Consistent with the conformational

167

flexibility of the RBD, 2D class averages showed heterogeneity in both occupancy and

168

conformation of bound Fabs for both groups (Fig. 4o-q). The 3D reconstructions of S-Fab

169

complexes revealed both a fully-occupied RBD and partial density for a second bound Fab,

170

suggesting that Fabs from both groups are able to recognize “up” and “down” states of the RBD

171

as previously described for some of the antibodies targeting this epitope12,13. The 3D

172

reconstructions are also consistent with BLI measurements indicating that Groups 1 and 2

173

antibodies bind a RBD epitope distinct from antibody CR3022, which is only accessible on the

174

RBD “up” conformational state11, and bind the RBD with different angles of approach, with Group

175

1 antibodies most similar to the approach angle of the SARS-CoV antibody S230 (Fig. 4r)14.

176
177

Human monoclonal antibodies with neutralizing activity against pathogens ranging from viruses

178

to parasites have been obtained from naturally infected individuals by single cell antibody cloning.

179

Several have been shown to be effective in protection and therapy in model organisms and in early

180

phase clinical studies, but only one antiviral monoclonal is currently in clinical use15. Antibodies

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

181

are relatively expensive and more difficult to produce than small molecule drugs. However, they

182

differ from drugs in that they can engage the host immune system through their constant domains

183

that bind to Fc gamma receptors on host immune cells16. These interactions can enhance immunity

184

and help clear the pathogen or infected cells, but they can also lead to disease enhancement during

185

Dengue17 and possibly coronavirus infections18. This problem has impeded Dengue vaccine

186

development but would not interfere with the clinical use of potent neutralizing antibodies that can

187

be modified to prevent Fc gamma receptor interactions and remain protective against viral

188

pathogens19.

189
190

Antibodies are essential elements of most vaccines and will likely be crucial component of an

191

effective vaccine against SARS-CoV-220(PMID:32434945; PMID:32434946). Recurrent

192

antibodies have been observed in other infectious diseases and vaccinal responses

193

al, in press, https://www.biorxiv.org/content/10.1101/2020.03.04.976159v1.full). The observation

194

that plasma neutralizing activity is low in most convalescent individuals, but that recurrent anti-

195

SARS-CoV-2 RBD antibodies with potent neutralizing activity can be found in individuals with

196

unexceptional plasma neutralizing activity suggests that humans are intrinsically capable of

197

generating anti-RBD antibodies that potently neutralize SARS-CoV-2. Thus, vaccines that

198

selectively and efficiently induce antibodies targeting the SARS-CoV-2 RBD may be especially

199

effective.

21-24

(Wang et

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

200

Table
Table 1. Cohort characteristics

201

Average
age
Case/Contact

Average duration
Sx
Sx onset
total
to visit

Average
Sx Severity
(0-10)

ELISA binding (AUC)
RBD
S
IgG
IgM
IgG
IgM

Neutralization
(NT50)

Gender

n

Male

83

45
(19-76)

65/18

12
(0-31)

39
(21-63)

5.8
(0-10)

2.44

1.61

4.65

1.62

867

Female

66

42
(19-75)

46/20

12
(1-35)

38
(17-67)

5.4
(1-9)

1.99

1.58

4.36

1.86

522

Sx=symptoms

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

202

Figures

203
204

Figure 1. Plasma antibodies against SARS-CoV-2. a-d, Graphs show results of ELISAs

205

measuring plasma reactivity to RBD (a, b) and S protein (c, d). Left shows optical density units at

206

450 nm (OD, Y axis) and reciprocal plasma dilutions (X axis). Negative controls in black;

207

individuals 21, and 47 in blue and red lines and arrowheads, respectively. Right shows normalized

208

area under the curve (AUC) for controls and each of 149 individuals in the cohort. e, Symptom

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

209

(Sx) onset to time of sample collection in days (X axis) plotted against normalized AUC for IgM

210

binding to RBD (Y axis) r=0.5517 and p=<0.0001. f, Participant age in years (X axis) plotted

211

against normalized AUC for IgG binding to RBD (Y axis) r=0.1827 and p=0.0258. The r and p

212

values for the correlations in e and f were determined by two-tailed Spearman’s. g, IgG anti-RBD

213

normalized AUC for outpatients and hospitalized individuals p=0.0178. h, IgG anti-RBD

214

normalized AUC for males and females p=0.0063. For g and h horizontal bars indicate median

215

values. Statistical significance was determined using two-tailed Mann-Whitney U test.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

216
217

Figure 2. Neutralization of SARS-CoV-2 pseudovirus by plasma. a, Graph shows normalized

218

relative luminescence values (RLU, Y axis) in cell lysates of 293TACE2 cells 48 hours after

219

infection with nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing

220

concentrations of plasma (X axis) derived from 149 participants (grey, except individuals 47 and

221

21 in red, and blue lines, bars and arrowheads, respectively) and 3 negative controls (black lines).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

222

Standard deviations of duplicates of one representative experiment are shown. b, Ranked average

223

half-maximal inhibitory plasma neutralizing titer (NT50) for the 59 of 149 individuals with NT50s

224

>500 and individual 107. See also Extended Data Table 1. Asterisks indicate donors from which

225

antibody sequences were derived. c, AUC for anti-RBD IgG ELISA (X axis) plotted against NT50

226

(Y axis) r=0.6432, p=<0.0001. d, AUC for anti-S IgG ELISA (X axis) plotted against NT50 (Y

227

axis) r=0.6721, p=<0.0001. e, NT50 for outpatients and hospitalized individuals p=0.0495. f, NT50

228

for all males and females in the cohort p=0.0031. Dotted line in c to f (NT50=5) represents lower

229

limit of detection (LLOD). Samples with undetectable neutralizing titers were plotted at LLOD.

230

Correlations in c and d were determined by two-tailed Spearman’s. Statistical significance in e and

231

f was determined using two-tailed Mann-Whitney U test. Horizontal bars indicate median values.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

232
233

Figure 3. Anti-SARS-CoV-2 RBD antibodies. a. Representative flow cytometry plots showing

234

dual AF647- and PE-RBD binding B cells in control and 6 study individuals (for gating strategy

235

see Extended Data Fig. 6). Percentages of antigen specific B cells are indicated. Control is a

236

healthy control sample obtained pre-COVID-19. b, Pie charts depicting the distribution of

237

antibody sequences from 6 individuals. The number in the inner circle indicates the number of

238

sequences analyzed for the individual denoted above the circle. White indicates sequences isolated

239

only once, and grey or colored pie slices are proportional to the number of clonally related

240

sequences. Red, blue, orange and yellow pie slices indicate clones that share the same IGHV and

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

241

IGLV genes. c, Circos plot shows sequences from all 6 individuals with clonal relationships

242

depicted as in b. Interconnecting lines indicate the relationship between antibodies that share V

243

and J gene segment sequences at both IGH and IGL. Purple, green and gray lines connect related

244

clones, clones and singles, and singles to each other, respectively. d, Sample sequence alignment

245

for antibodies originating from different individuals that display highly similar IGH V(D)J and

246

IGL VJ sequences including CDR3s. Amino acid differences in CDR3s to the bolded reference

247

sequence above are indicated in red and dots represent identities.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

248
249

Figure 4. Anti-SARS-CoV-2 RBD antibody reactivity. a, Graph show results of ELISA assays

250

measuring monoclonal antibody reactivity to RBD. Optical density units at 450 nm (OD, Y axis)

251

vs. antibody concentrations (X axis). C121, C135 C144 and isotype control in red, green, purple,

252

and black respectively, in all panels. b, Graph shows normalized relative luminescence values

253

(RLU, Y axis) in cell lysates of 293TACE2 cells 48 hours after infection with SARS-CoV-2

254

pseudovirus in the presence of increasing concentrations of monoclonal antibodies (X axis). c,

255

RLU for SARS-CoV-2 pseudovirus assay (Y axis) vs. titration of monoclonal antibodies C121,

256

C135 and C144 in one of two independent experiments (see Extended Data Table 6). d, SARS-

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

257

CoV-2 real virus neutralization assay. Infected cells (Y axis) vs. titration of monoclonal antibodies

258

C121, C135 and C144 in two independent experiments. For a and b panels, isotype control

259

antibody in black. e, IC50s for antibodies assayed in b and d. f, Diagrammatic representation of

260

biolayer interferometry experiment. g, Graph shows binding of C144, C101, C121, C009, C135,

261

and CR302210,11 to RBD. h-m, Secondary antibody binding to preformed IgG-RBD complexes

262

(Ab1). The table displays the shift in nanometers after second antibody (Ab2) binding to the

263

antigen in the presence of the first antibody (Ab1). Values are normalized by the subtraction of the

264

autologous antibody control. o-q, Representative 2D-class averages and 3D reconstructed

265

volumes for SARS-CoV-S 2P trimers complexed with C002, C119, and C121 Fabs. 2D-class

266

averages with observable Fab density are boxed. r, Overlay of S-Fab complexes with fully-

267

occupied C002 (blue), C121 (magenta) and C119 (orange) Fabs aligned on the RBD “up”

268

conformational state. The SARS-CoV-2 S model with 1 “up” RBD state (PDB 6VYB) was fit into

269

the density and the SARS-CoV antibody S230 (PDB 6NB6) shown as reference (green ribbon).

270
271

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

272

Methods

273

Study participants. Study participants were recruited at the Rockefeller University Hospital in

274

New York from April 1 through May 8, 2020. Eligible participants were adults aged 18-76 years

275

who were either diagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptoms

276

of COVID-19 for at least 14 days (cases), or who were close contacts (e.g., household, co-workers,

277

members of same religious community) with someone who had been diagnosed with SARS-CoV-

278

2 infection by RT-PCR and were free of symptoms suggestive of COVID-19 for at least 14 days

279

(contacts). Exclusion criteria included presence of symptoms suggestive of active SARS-CoV-2

280

infection, or hemoglobin < 12 g/dL for males and < 11 g/dL for females.

281

Most study participants were residents of the Greater New York City tri-state region and were

282

enrolled sequentially according to eligibility criteria. Participants were first interviewed by phone

283

to collect information on their clinical presentation, and subsequently presented to the Rockefeller

284

University Hospital for a single blood sample collection. Participants were asked to rate the

285

highest severity of their symptoms on a numeric rating scale ranging from 0 to 10. The score was

286

adapted from the pain scale chart, where 0 was the lack of symptoms, 4 were distressing symptoms

287

(e.g. fatigue, myalgia, fever, cough, shortness of breath) that interfered with daily living activities,

288

7 were disabling symptoms that prevented the performance of daily living activities, and 10 was

289

unimaginable/unspeakable discomfort (in this case, distress due to shortness of breath). All

290

participants provided written informed consent before participation in the study and the study was

291

conducted in accordance with Good Clinical Practice.

292
293

Blood samples processing and storage. Peripheral Blood Mononuclear Cells (PBMCs) were

294

obtained by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

295

DMSO. Heparinized plasma and serum samples were aliquoted and stored at -20°C or less. Prior

296

to experiments, aliquots of plasma samples were heat-inactivated (56C for 1 hour) and then stored

297

at 4C.

298
299

Cloning, expression and purification of recombinant coronavirus proteins. Codon-optimized

300

nucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues 16-1206) and receptor

301

binding domain (RBD; residues 331-524) were synthesized and subcloned into the mammalian

302

expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies based on an early

303

SARS-CoV-2 sequence isolate (GenBank MN985325.1). The SARS-CoV-2 RBD construct

304

included an N-terminal human IL-2 signal peptide and dual C-terminal tags ((GGGGS)2-

305

HHHHHHHH (octa-histidine), and GLNDIFEAQKIEWHE (AviTag)). In addition, the

306

corresponding S1B or receptor binding domains for SARS-CoV S (residues 318-510; GenBank

307

AAP13441.1), MERS-CoV S (residues 367-588; GenBank JX869059.2), HCoV-NL63 (residues

308

481-614; GenBank AAS58177.1), HCoV-OC43 (residues 324-632; GenBank AAT84362.1), and

309

HCoV-229E (residues 286-434; GenBank AAK32191.1) were synthesized with the same N- and

310

C-terminal extensions as the SARS-CoV-2 RBD construct and subcloned into the mammalian

311

expression pTwist-CMV BetaGlobin vector (Twist Bioscience Technologies). The SARS-CoV-2

312

S ectodomain was modified as previously described 4. Briefly, the S ectodomain construct included

313

an N-terminal mu-phosphatase signal peptide, 2P stabilizing mutations (K986P and V987P),

314

mutations to remove the S1/S2 furin cleavage site (682RRAR685 to GSAS), a C-terminal extension

315

(IKGSG-RENLYFQG (TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL

316

(foldon trimerization motif), G-HHHHHHHH (octa-histidine tag), and GLNDIFEAQKIEWHE

317

(AviTag)). The SARS-CoV-2 S 2P ectodomain and RBD constructs were produced by transient

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

318

transfection of 500 mL of Expi293 cells (Thermo Fisher) and purified from clarified transfected

319

cell supernatants four days post-transfection using Ni2+-NTA affinity chromatography (GE Life

320

Sciences). Affinity-purified proteins were concentrated and further purified by size-exclusion

321

chromatography (SEC) using a Superdex200 16/60 column (GE Life Sciences) running in 1x TBS

322

(20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.02% NaN3). Peak fractions were analyzed by SDS-

323

PAGE, and fractions corresponding to soluble S 2P trimers or monomeric RBD proteins were

324

pooled and stored at 4˚C.

325
326

ELISAs. ELISAs to evaluate antibodies binding to SARS-CoV-2 RBD and trimeric spike proteins

327

were performed by coating of high binding 96 half well plates (Corning #3690) with 50 µL per

328

well of a 1µg/mL protein solution in PBS overnight at 4°C. Plates were washed 6 times with

329

washing buffer (1xPBS with 0.05% Tween 20 (Sigma-Aldrich)) and incubated with 170 µL per

330

well blocking buffer (1xPBS with 2% BSA and 0.05% Tween20 (Sigma)) for 1 hour at room

331

temperature (RT). Immediately after blocking, monoclonal antibodies or plasma samples were

332

added in PBS and incubated for 1 hr at RT. Plasma samples were assayed at a 1:200 starting

333

dilution and seven additional 3-fold serial dilutions. Monoclonal antibodies were tested at 10µg/ml

334

starting concentration and 10 additional 4-fold serial dilutions. Plates were washed 6 times with

335

washing buffer and then incubated with anti-human IgG or IgM secondary antibody conjugated to

336

horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088 and 109-035-129) in

337

blocking buffer at a 1:5000 dilution. Plates were developed by addition of the HRP substrate, TMB

338

(ThermoFisher) for 10 minutes, then the developing reaction was stopped by adding 50µl 1M

339

H2SO4 and absorbance was measured at 450nm with an ELISA microplate reader (FluoStar

340

Omega, BMG Labtech). For plasma samples, a positive control (plasma from patient COV21,

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

341

diluted 200-fold in PBS) was added in duplicate to every assay plate. The average of its signal was

342

used for normalization of all the other values on the same plate with Excel software prior to

343

calculating the area under the curve using Prism 8 (GraphPad). For monoclonal antibodies, the

344

half-maximal effective concentration (EC50) was determined using 4-parameter nonlinear

345

regression (GraphPad Prism).

346
347

293TACE2 cells. For constitutive expression of ACE2 in 293T cells, a cDNA encoding ACE2,

348

carrying two inactivating mutations in the catalytic site (H374N & H378N), was inserted into CSIB

349

3’ to the SFFV promoter25. 293TACE2 cells were generated by transduction with CSIB based virus

350

followed by selection with 5 µg/ml Blasticidin.

351
352

SARS-CoV-2 and SARS-CoV pseudotyped reporter viruses. A plasmid expressing a C-

353

terminally truncated SARS-CoV-2 S protein (pSARS-CoV2-Strunc) was generated by insertion of

354

a human-codon optimized cDNA encoding SARS-CoV-2 S lacking the C-terminal 19 codons

355

(Geneart) into pCR3.1. The S ORF was taken from “Wuhan seafood market pneumonia virus

356

isolate Wuhan-Hu-1” (NC_045512). For expression of full-length SARS-CoV S protein, “Human

357

SARS coronavirus Spike glycoprotein Gene ORF cDNA clone expression plasmid (Codon

358

Optimized)” (here referred to as pSARS-CoV-S) was obtained from SinoBiological (Cat:

359

VG40150-G-N). An env-inactivated HIV-1 reporter construct (pNL4-3DEnv-nanoluc) was

360

generated from pNL4-326 by introducing a 940 bp deletion 3’ to the vpu stop-codon, resulting in a

361

frameshift in env. The human codon-optimized nanoluc Luciferase reporter gene (Nluc, Promega)

362

was inserted in place of nucleotides 1-100 of the nef-gene. To generate pseudotyped viral stocks,

363

293T cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV2-Strunc or pSARS-CoV-

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

364

S using polyethyleneimine. Co-transfection of pNL4-3DEnv-nanoluc and S-expression plasmids

365

leads to production of HIV-1-based virions carrying either the SARS-CoV-2 or SARS-CoV spike

366

protein on the surface. Eight hours after transfection, cells were washed twice with PBS and fresh

367

media was added. Supernatants containing virions were harvested 48 hours post transfection,

368

filtered and stored at -80°C. Infectivity of virions was determined by titration on 293TACE2 cells.

369
370

Pseudotyped virus neutralization assay. Five-fold serially diluted plasma from COVID-19

371

convalescent individuals and healthy donors or four-fold serially diluted monoclonal antibodies

372

were incubated with the SARS-CoV-2 or SARS-CoV pseudotyped virus for 1 hour at 37°C

373

degrees. The mixture was subsequently incubated with 293TACE2 cells for 48 hours after which

374

cells were washed twice with PBS and lysed with Luciferase Cell Culture Lysis 5x reagent

375

(Promega). Nanoluc Luciferase activity in lysates was measured using the Nano-Glo Luciferase

376

Assay System (Promega). Relative luminescence units obtained were normalized to those derived

377

from cells infected with SARS-CoV-2 or SARS-CoV pseudotyped virus in the absence of plasma

378

or monoclonal antibodies. The half-maximal inhibitory concentration for plasma (NT50) or

379

monoclonal antibodies (IC50) was determined using 4-parameter nonlinear regression (GraphPad

380

Prism).

381

Cell lines, virus and virus titration. VeroE6 kidney epithelial cells (Chlorocebus sabaeus) and

382

Huh-7.5 hepatoma cells (H. sapiens) were cultured in Dulbecco’s Modified Eagle Medium

383

(DMEM) supplemented with 1% nonessential amino acids (NEAA) and 10% fetal bovine serum

384

(FBS) at 37oC and 5% CO2. All cell lines have been tested negative for contamination with

385

mycoplasma and were obtained from the ATCC (with the exception for Huh-7.5).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

386

SARS-CoV-2, strain USA-WA1/2020, was obtained from BEI Resources and amplified in VeroE6

387

cells at 33°C. Viral titers were measured on Huh-7.5 cells by standard plaque assay (PA). Briefly,

388

500 µL of serial 10-fold virus dilutions in Opti-MEM were used to infect 400,000 cells seeded the

389

day prior in a 6-well plate format. After 90 min adsorption, the virus inoculum was removed, and

390

cells were overlayed with DMEM containing 10% FBS with 1.2% microcrystalline cellulose

391

(Avicel). Cells were incubated for five days at 33°C, followed by fixation with 3.5% formaldehyde

392

and crystal violet staining for plaque enumeration. All experiments were performed in a biosafety

393

level 3 laboratory.

394

Microscopy-based neutralization assay of authentic SARS-CoV-2. The day prior to infection

395

VeroE6 cells were seeded at 12,500 cells/well into 96-well plates. Antibodies were serially diluted

396

in BA-1, mixed with a constant amount of SARS-CoV-2 (grown in VeroE6) and incubated for 60

397

min at 37°C. The antibody-virus-mix was then directly applied to VeroE6 cells (MOI of ~0.1

398

PFU/cell). Cells were fixed 18 hours post infection by adding an equal volume of 7% formaldehyde

399

to the wells, followed by permeabilization with 0.1% Triton X-100 for 10 min. After extensive

400

washing, cells were incubated for 1 hour at room temperature with blocking solution of 5% goat

401

serum in PBS (catalog no. 005–000-121; Jackson ImmunoResearch). A rabbit polyclonal anti-

402

SARS-CoV-2 nucleocapsid antibody (catalog no. GTX135357; GeneTex) was added to the cells

403

at 1:500 dilution in blocking solution and incubated at 4°C overnight. A goat anti-rabbit

404

AlexaFluor 594 (catalog no. A-11012; Life Technologies) at a dilution of 1:2,000 was used as a

405

secondary antibody. Nuclei were stained with Hoechst 33342 (catalog no. 62249; Thermo

406

Scientific) at a 1:1,000 dilution. Images were acquired with a fluorescence microscope and

407

analyzed using ImageXpress Micro XLS (Molecular Devices, Sunnyvale, CA). All statistical

408

analyses were done using Prism 8 software (GraphPad).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

409

Biotinylation of viral protein for use in flow cytometry. Purified and Avi-tagged SARS-CoV-2

410

RBD was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer’s

411

instructions (Avidity). Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-

412

NHS-LC-Biotinylation kit according to the manufacturer’s instructions (Thermo Scientific).

413

Biotinylated Ovalbumin was conjugated to streptavidin-BV711 (BD biosciences, 563262) and

414

RBD to streptavidin-PE (BD biosciences, 554061) and streptavidin-Alexa Fluor 647 (AF647,

415

Biolegend, 405237) respectively27.

416
417

Single cell sorting by flow cytometry. PBMCs were enriched for B cells by negative selection

418

using a pan B cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-

419

101-638). The enriched B cells were incubated in FACS buffer (1 X Phosphate-buffered Saline

420

(PBS), 2% calf serum, 1 mM EDTA) with the following anti-human antibodies: anti-CD20-PECy7

421

(BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-

422

eFluro 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluro 780 (Invitrogen, 47-0168-41), anti-

423

CD14-APC-eFluro 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105),

424

and fluorophore-labeled RBD and Ovalbumin for 30 minutes on ice27. Single CD3-CD8-CD16-

425

CD20+Ova-RBD-PE+RBD-AF647+ B cells were sorted into individual wells of a 96-well plates

426

containing 4 μl of lysis buffer (0.5 X PBS, 10mM DTT, 3000 units/mL RNasin Ribonuclease

427

Inhibitors (Promega, N2615) per well using a FACS Aria III (Becton Dickinson). The sorted cells

428

were frozen on dry ice, and then stored at −80°C or immediately used for subsequent RNA reverse

429

transcription. Although cells were not stained for IgG expression, they are memory B cells based

430

on the fact that they are CD20+ (a marker absent in plasmablasts) and they express IgG (since

431

antibodies were amplified from these cells using IgG-specific primers).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

432
433

Antibody sequencing, cloning and expression. Antibodies were identified and sequenced as

434

described previously22,28,29. Briefly, RNA from single cells was reverse-transcribed (SuperScript

435

III Reverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at -20°C or used for

436

subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger

437

sequencing28. Amplicons from the first PCR reaction were used as templates for Sequence- and

438

Ligation-Independent Cloning (SLIC) into antibody expression vectors. Recombinant monoclonal

439

antibodies and Fabs were produced and purified as previously described30,31.

440
441

Biolayer interferometry.

442

BLI assays were performed on the Octet Red instrument (ForteBio) at 30°C with shaking at 1,000

443

r.p.m. Epitope binding assays were performed with protein A biosensor (ForteBio 18-5010),

444

following the manufacture protocol “classical sandwich assay”. (1) Sensor check: sensors

445

immersed 30 sec in buffer alone (buffer ForteBio 18-1105). (2) Capture 1st Ab: sensors immersed

446

10min with Ab1 at 40 µg/mL. (3) Baseline: sensors immersed 30sec in buffer alone. (4) Blocking:

447

sensors immersed 5 min with IgG isotype control at 50 µg/mL. (6) Antigen association: sensors

448

immersed 5 min with RBD at 100 µg/mL. (7) Baseline: sensors immersed 30 sec in buffer alone.

449

(8) Association Ab2: sensors immersed 5min with Ab2 at 40 µg/mL. Curve fitting was performed

450

using the Data analysis software (ForteBio).

451
452

Computational analyses of antibody sequences. Antibody sequences were trimmed based on

453

quality and annotated using Igblastn v1.14.032 with IMGT domain delineation system. Annotation

454

was performed systematically using Change-O toolkit v.0.4.533. Heavy and light chains derived

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

455

from the same cell were paired, and clonotypes were assigned based on their V and J genes using

456

in-house R and Perl scripts (Fig. 3 b,c). All scripts and the data used to process antibody sequences

457

are publicly available on GitHub (https://github.com/stratust/igpipeline).

458

The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study

459

was compared to Sequence Read Archive SRP01097034. The V(D)J assignments were done using

460

IMGT/High V-Quest and the frequencies of heavy and light chain V genes were calculated for 14

461

and 13 individuals, respectively, using sequences with unique CDR3s. The two-tailed t test with

462

unequal variances was used to determine statistical significance (Extended Data Fig. 7).

463

Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl

464

scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against

465

their closest germlines using IgBlast and the number of differences were considered nucleotide

466

mutations. The average mutations for V genes was calculated by dividing the sum of all nucleotide

467

mutations across all patients by the number of sequences used for the analysis. To calculate the

468

GRAVY scores of hydrophobicity35 we used Guy H.R. Hydrophobicity scale based on free energy

469

of transfer (kcal/mole)36 implemented by the R package Peptides available in the Comprehensive

470

R Archive Network repository (https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-

471

001.pdf). We used 534 heavy chain CDR3 amino acid sequences from this study and 22,654,256

472

IGH CDR3 sequences from the public database of memory B-cell receptor sequences37. The

473

Shapiro-Wilk test was used to determine whether the GRAVY scores are normally distributed.

474

The GRAVY scores from all 533 IGH CDR3 amino acid sequences from this study

475

(sequence COV047_P4_IgG_51-P1369 lacks CDR3 amino acid sequence) were used to perform

476

the test and 5000 GRAVY scores of the sequences from the public database were randomly

477

selected. The Shapiro-Wilk p-values were 6.896 x 10-3 and 2.217 x 10-6 for sequences from this

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

478

study and the public database, respectively, indicating the data are not normally distributed.

479

Therefore, we used the Wilcoxon non-parametric test to compare the samples, which indicated a

480

difference in hydrophobicity distribution (p = 5 x 10-6; Extended Data Fig. 8).

481
482

Negative-stain EM Data Collection and Processing

483

Purified Fabs (C002, C119, and C121) were complexed with SARS-CoV-2 S trimer at a 2-fold

484

molar excess for 1 min and diluted to 40 µg/mL in TBS immediately before adding 3 µL to a

485

freshly-glow discharged ultrathin, 400 mesh carbon-coated copper grid (Ted Pella, Inc.). Samples

486

were blotted after a 1 min incubation period and stained with 1% uranyl formate for an additional

487

minute before imaging. Micrographs were recorded on a Thermo Fisher Talos Arctica transmission

488

electron microscope operating at 200 keV using a K3 direct electron detector (Gatan, Inc) and

489

SerialEM automated image acquisition software38. Images were acquired at a nominal

490

magnification of 28,000x (1.44 Å/pixel size) and a -1.5 to -2.0 µm defocus range. Images were

491

processed in cryoSPARC v2.14, and reference-free particle picking was completed using a

492

gaussian blob picker39. Reference-free 2D class averages and ab initio volumes were generated in

493

cryoSPARC, and subsequently 3D-classified to identify classes of S-Fab complexes, that were

494

then homogenously refined. Figures were prepared using UCSF Chimera40.

495

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

496

Acknowledgements: We thank all study participants who devoted time to our research; Drs. Barry

497

Coller and Sarah Schlesinger, the Rockefeller University Hospital Clinical Research Support

498

Office and nursing staff. Dr. Joseph L. DeRisi for facilitating interactions with the Chan

499

Zuckerberg BioHub. All members of the M.C.N. laboratory for helpful discussions, Drs. Amelia

500

Escolano, Gaëlle Breton and Bernardo Reis, and Maša Jankovic for laboratory support. This work

501

was supported by NIH grant P01-AI138398-S1 (M.C.N., C.M.R., P.J.B.) and 2U19AI111825

502

(M.C.N. and C.M.R).; the Caltech Merkin Institute for Translational Research and P50 AI150464

503

(P.J.B.), George Mason University Fast Grant and the European ATAC consortium (EC

504

101003650) to D.F.R.; 3 R01-AI091707-10S1 to C.M.R.; R37-AI64003 to P.D.B.; R01AI78788

505

to T.H.; The G. Harold and Leila Y. Mathers Charitable Foundation to C.M.R.. Electron

506

microscopy was performed in the Caltech Beckman Institute Resource Center for Transmission

507

Electron Microscpy (Drs. Songye Chen and Andrey Malyutin, Directors). C.G. was supported by

508

the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing

509

Translational Sciences (National Institutes of Health Clinical and Translational Science Award

510

program, grant UL1 TR001866), and by the Shapiro-Silverberg Fund for the Advancement of

511

Translational Research. P.D.B. and M.C.N. are Howard Hughes Medical Institute Investigators.

512
513

Contributions: D.F.R., P.D.B., P.J.B., T.H., C.M.R. and M.C.N. conceived, designed and

514

analyzed the experiments. D.F.R., M.C. and C.G. designed clinical protocols. F.M., J.C.C.L.,

515

Z.W., A.C., M.A., C.O.B., S.F., T.H., C.V., K.G., F.B., S.T.C., P.M., H.H., L.N., F.S., Y.W., H.-

516

H.H., E.M., A.W.A., K.E.H.T., N.K. and P.R.H. carried out all experiments. A.G. and M.C.

517

produced antibodies. C.O.B., J.P. and E.W. produced SARS-CoV-2 proteins. A.H., R.K., J.H.,

518

K.G.M., C.G. and M.C. recruited participants and executed clinical protocols. R.P., J.D., M.P. and

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

519

I.S. processed clinical samples. T.Y.O., A.P.W. and V.R. performed bioinformatic analysis.

520

D.F.R., P.D.B., P.J.B., T.H., C.M.R. and M.C.N. wrote the manuscript with input from all co-

521

authors.

522
523

Declaration of conflict: In connection with this work The Rockefeller University has filed a

524

provisional patent application on which D.F.R. and M.C.N. are inventors.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

525

Extended Data Tables
Extended Data Table 1. Individual participant demographics and clinical characteristics
Sx
Duration (days)
Sx
Sx onset Severity
ID
Age Gender Race
Ethnicity
Case/Contact
total
to visit
(0-10)

526

5
7
8
9
12
13
18
20
21
24
26
27
28
29
30
31
32
37
38
40
41
42
45
46
47
48
50
51
54
55
56
57
58
64
67
71
72
75
76
77
81
82
88
95
96
97
98
99
107
108
110
114
115
119
120
121
122
123
124
125
127
130
131
132
134
135
140
149
150
154
157
166
167
172
173
178
179
182
183
185
186
190
195
200
201
202
205
222
229
230
232
233
241

43
40
37
35
27
28
55
26
54
34
66
28
26
26
30
51
46
27
57
44
35
40
55
39
43
37
27
21
40
36
75
66
64
28
19
45
42
46
49
37
44
46
41
44
48
39
35
36
53
75
27
30
65
56
56
19
21
26
63
51
24
39
39
36
27
62
63
41
50
68
50
28
50
38
47
26
39
44
43
54
38
54
24
60
50
57
64
28
45
50
38
55
36

M
M
M
F
F
M
M
F
M
M
M
M
M
F
M
M
F
M
F
M
M
M
F
M
F
F
F
M
F
M
F
M
F
F
F
F
M
F
F
M
F
M
M
M
F
M
F
F
F
M
M
F
F
M
F
M
F
M
F
F
F
M
M
M
F
F
F
M
F
M
M
F
F
F
M
F
M
F
F
M
F
F
M
F
M
M
M
M
M
M
F
M
M

White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
N/A
White
White
White
White
White
White
N/A
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
Asian
White
White
White
White
White
White
White
White
White
White
Asian
White
White
White
White
White
White
White
White
White
White
N/A
White
White
White
White
White
White
Asian
White
White
White
White
White

Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
N/A
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic

Case
Case
Case
Case
Contact
Case
Case
Case
Contact
Case
Case
Case
Case
Contact
Contact
Case
Case
Case
Case
Case
Contact
Contact
Case
Case
Case
Case
Contact
Contact
Contact
Case
Case
Case
Contact
Contact
Case
Case
Case
Case
Case
Contact
Contact
Case
Case
Case
Case
Case
Case
Case
Contact
Case
Case
Case
Contact
Case
Case
Contact
Contact
Contact
Contact
Case
Case
Contact
Case
Contact
Contact
Case
Case
Contact
Contact
Case
Case
Case
Contact
Case
Case
Case
Contact
Contact
Case
Case
Case
Case
Case
Case
Contact
Case
Case
Case
Case
Case
Case
Case
Case

9
11
3
12
7
5
16
2
11
15
2
9
7
5
3
9
8
6
10
7
10
20
7
8
11
7
7
8
3
3
22
6
1
11
5
12
16
10
28
6
3
0
7
9
9
9
2
13
10
16
1
15
20
13
26
3
3
12
4
10
10
7
5
10
16
8
28
17
12
16
10
13
11
8
5
6
10
10
13
11
8
18*
18
17
15
21
7
11
10
18
13
20
12

41
30
57
54
24
25
28
17
27
30
35
32
21
35
35
33
32
28
38
23
29
36
48
30
33
21
28
31
24
49
40
21
32
32
29
48
35
36
34
33
35
23
36
30
31
24
29
29
41
25
36
41
48
48
42
38
34
37
26
43
28
25
50
22
31
47
28
45
30
32
45
41
22
47
24
37
38
44
44
26
63
42
39
33
34
36
29
63
33
43
41
30

9
6
5
5
3
3
6
5
7
4
3
4
4
4
4
3
3
6
4
5
8
8
6
2
5
5
4
5
3
2
3
5
2
6
6
7
8
4
4
4
2
0
4
6
3
3
4
5
4
7
1
7
6
3
6
2
1
6
3
3
6
5
4
6
5
6
1
6
7
9
8
2
6
9
7
4
3
6
8
8
2
9
5
7
6
7
4
7
4
7
7
3

ELISA binding (AUC)
RBD
S
IgG
IgM
IgG
IgM
2.52
2.92
2.11
2.90
1.47
1.97
2.57
1.80
5.60
2.29
1.67
1.79
2.39
1.69
3.07
1.29
1.30
2.13
1.87
1.72
2.13
2.37
1.95
2.68
3.02
1.51
1.64
1.76
1.80
1.43
1.79
1.54
1.20
2.36
2.56
1.55
4.05
1.64
1.88
1.33
1.58
2.19
1.82
2.61
3.93
1.58
1.78
2.50
1.74
1.37
1.30
1.65
2.10
1.36
0.99
0.85
1.44
0.94
1.58
1.92
1.80
1.24
1.46
2.15
2.51
2.20
1.05
1.68
1.15
3.19
2.40
1.27
1.43
1.71
2.57
1.54
1.89
3.80
1.56
3.51
1.73
3.24
2.74
2.40
4.37
2.10
4.51
1.28
2.92
3.80
1.57
2.07

2.35
2.54
0.81
1.07
1.71
4.10
1.75
2.00
2.88
1.97
1.86
1.64
2.25
1.54
2.55
1.60
2.18
1.52
2.02
1.50
1.67
1.50
0.97
1.45
2.30
1.85
2.32
1.69
2.10
1.23
1.81
2.10
1.71
2.06
1.98
2.04
3.58
2.37
1.65
1.83
1.73
1.92
3.32
1.62
1.93
1.61
1.47
3.27
1.41
0.88
1.60
1.92
3.28
1.26
0.97
0.87
0.94
0.95
2.06
3.49
2.50
1.72
1.38
1.76
2.18
2.02
1.24
2.02
0.43
2.19
2.86
0.66
3.71
2.58
4.14
1.59
2.25
1.77
1.02
1.39
2.47
1.24
2.55
1.00
2.57
2.08
0.70
0.69
1.42
0.47
0.70
2.11

5.51
7.39
4.46
4.44
4.31
3.95
3.92
4.49
7.60
4.36
4.00
4.41
4.93
3.93
4.86
4.69
3.79
4.11
4.30
3.81
4.15
5.82
3.53
4.14
6.23
3.47
5.42
3.94
4.99
3.90
5.89
4.33
3.95
4.48
5.48
3.86
6.05
3.98
5.17
3.56
3.82
5.41
4.97
6.03
6.25
4.03
5.38
4.38
4.66
3.47
4.00
3.53
4.32
4.41
3.65
3.56
3.39
3.39
3.49
3.86
4.37
3.91
4.44
4.84
6.84
3.80
3.58
3.67
3.18
4.85
3.90
3.45
3.93
4.29
4.78
3.66
3.83
5.36
3.88
5.55
4.37
7.38
5.01
4.38
6.15
5.07
6.12
3.94
4.90
3.48
4.24
4.51
4.54

2.43
2.37
0.88
2.80
1.23
1.38
1.31
1.68
2.47
1.45
1.58
1.30
1.66
1.97
1.34
1.20
0.83
1.04
1.12
1.47
0.98
1.43
0.75
1.29
2.66
1.51
1.45
1.03
1.42
2.09
1.47
1.00
1.21
1.66
1.32
1.53
2.59
1.20
0.97
1.16
1.10
1.81
1.37
1.62
2.26
2.33
1.22
2.49
0.90
1.36
0.93
1.55
3.27
1.59
1.21
1.26
1.22
1.40
1.32
1.24
2.41
1.34
1.03
1.97
1.94
1.13
1.28
1.09
1.82
1.29
2.06
0.94
8.74
1.20
4.48
1.02
1.73
8.05
1.55
2.11
1.23
1.42
2.33
1.51
1.57
1.17
1.69
3.46
1.58
0.88
5.70
1.07
1.46

Neutralization
(NT50)
5.0
2730.4
5.0
5.0
5.0
173.2
410.3
5.0
5052.7
280.7
276.1
739.3
888.9
5.0
5.0
192.3
47.4
286.3
518.9
42.1
302.5
627.1
5.0
59.2
10433.3
173.4
924.7
1499.2
5.0
5.0
1388.4
2048.9
5.0
776.7
2052.9
33.3
3138.2
271.5
219.8
5.0
5.0
130.7
424.7
961.9
927.7
202.7
249.0
1127.6
297.5
557.5
5.0
110.9
1127.7
650.3
100.6
5.0
5.0
5.0
5.0
126.5
883.5
5.0
7.8
5.0
2700.6
350.0
52.4
494.9
5.0
928.2
741.7
5.0
5.0
301.1
646.9
5.0
370.1
1503.7
240.1
1806.8
296.9
598.1
1315.1
1014.4
3897.4
257.9
924.4
5.0
1272.9
5.0
94.3
173.2

157

50

M

White Non-Hispanic

Case

10

32

8

2.40

2.86

3.90

2.06

741.7

166
28
F
White Non-Hispanic
Case
13
45
3.45
0.94
1.27
0.66
5.0
bioRxiv preprint doi:
https://doi.org/10.1101/2020.05.13.092619
; this
version
posted26 May 22,
2020.
The copyright
holder for
this preprint (which
167
50
F
White Non-Hispanic
Contact
11
41
3.93
8.74
1.43
3.71
5.0
was not certified
peer review)
is the
author/funder,
the
It is made
172 by38
F
White
Non-Hispanic
Case who has8 granted
22bioRxiv 9a license
4.29preprint
1.20 in perpetuity.
1.71to display
2.58
301.1
available under
173
47
M
White Non-Hispanic
Case aCC-BY-NC-ND
5
474.0 International
4.78
4.48
7
2.57license
4.14.
646.9
178
179
182
183
185
186
190
195
200
201
202
205
222
229
230
232
233
241
242
243
246
255
256
258
279
280
302
310
314
315
319
323
325
343
352
353
356
357
364
366
373
388
393
394
397
403
406
410
421
426
437
460
461
462
470
478
481
486
500
501
502
506
507
509
526
537
539
547
587
632
633
652
664
675

26
39
44
43
54
38
54
24
60
50
57
64
28
45
50
38
55
36
59
30
44
33
63
52
41
59
47
34
46
29
50
39
52
21
44
60
22
27
29
41
35
47
69
48
52
52
65
34
62
65
43
36
49
28
28
31
28
64
46
32
52
46
39
36
49
52
73
59
54
38
39
76
45
47

F
M
F
F
M
F
F
M
F
M
M
M
M
M
M
F
M
M
M
F
F
M
F
M
M
M
F
F
M
F
M
F
M
F
M
M
F
F
M
F
F
F
M
F
M
M
M
M
F
M
F
M
M
F
F
M
F
F
M
M
M
M
M
M
M
M
F
M
M
M
M
M
F
M

White
White
White
White
White
N/A
White
White
White
White
White
White
Asian
White
White
White
White
White
White
Asian
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
White
Multiple
White
Asian
White
White
White
White
Asian
White
White
White
White
White
Asian
White
White
Asian
White
White
White
White
Asian
White
White
White
PI
White
White
White
White
White

*hospitalized, Sx=symptoms

527

Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
N/A
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
N/A
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic
Non-Hispanic

Case
Contact
Contact
Case
Case
Case
Case
Case
Case
Contact
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Contact
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Contact
Contact
Contact
Contact
Case
Contact
Case
Case
Case
Case
Case
Case
Contact
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Case
Contact
Contact
Case
Case
Contact

6
10
10
13
11
8
18*
18
17
15
21
7
11
10
18
13
20
12
10
6
10
14
27
14
7
6
35*
17
11
15
5
7
16
16
16
14
16
34
14
9
12
14
23*
7
22
18*
20
12
12
18
14
11
7
16
17
16
15
11
12
18*
16*
12
15
11
11
15
19*
15*
17*
10
8
18*
17*
31

24
37
38
44
44
26
63
42
39
33
34
36
29
63
33
43
41
30
42
26
38
44
42
48
38
32
49
35
38
42
38
45
38
49
43
49
38
56
49
34
51
41
54
67
45
39
56
46
43
51
34
39
39
45
51
52
43
41
53
53
53
59
60
50
34
45
54
36
51
43
57
56
42
47

4
3
6
8
8
2
9
5
7
6
7
4
7
4
7
7
3
7
6
5
7
6
6
6
8
7
7
5
7
8
6
7
8
5
4
6
3
5
6
7
7
9
9
4
8
10
8
8
9
6
7
6
5
5
4
4
8
10
5
10
9
9
8
5
7
6
10
9
8
6
4
10
10
5

1.54
1.89
3.80
1.56
3.51
1.73
3.24
2.74
2.40
4.37
2.10
4.51
1.28
2.92
3.80
1.57
2.07
2.27
4.91
2.92
2.05
2.14
1.72
2.64
1.68
2.53
1.48
3.95
2.12
3.02
3.71
1.05
2.25
1.63
3.54
5.38
1.37
7.49
0.97
0.98
1.69
1.57
1.28
2.05
3.32
5.36
4.69
1.06
0.95
2.07
2.54
2.94
3.38
1.36
1.26
1.43
1.70
1.70
1.10
2.62
5.10
0.84
1.92
1.99
3.36
1.47
2.82
2.97
3.22
2.49
1.25
4.75
1.68
0.79

1.59
2.25
1.77
1.02
1.39
2.47
1.24
2.55
1.00
2.57
2.08
0.70
0.69
1.42
0.47
0.70
2.11
2.66
1.94
2.57
2.79
0.70
1.96
1.20
2.13
3.07
0.97
1.24
0.88
0.69
2.28
1.03
1.47
0.94
0.92
1.12
0.61
1.10
0.58
0.52
1.26
1.06
1.74
0.87
0.59
1.09
0.90
0.56
1.07
0.55
0.47
3.18
0.94
0.38
0.86
0.93
0.39
1.00
0.82
0.65
0.61
0.81
0.96
1.01
1.45
0.95
0.63
1.53
0.60
0.86
1.04
1.46
0.43
0.93

3.66
3.83
5.36
3.88
5.55
4.37
7.38
5.01
4.38
6.15
5.07
6.12
3.94
4.90
3.48
4.24
4.51
4.54
4.81
5.06
6.09
4.20
4.26
4.52
3.77
4.61
4.06
9.44
4.56
3.98
3.79
3.53
4.83
3.37
4.50
5.69
2.98
2.77
2.90
3.51
5.14
3.61
3.81
4.34
5.01
10.01
7.51
3.95
3.34
3.95
4.30
5.51
4.67
3.07
3.97
3.70
3.46
3.68
3.49
4.51
5.10
3.13
4.56
3.99
5.88
3.65
4.46
5.08
4.01
4.50
3.38
8.96
3.93
2.94

1.02
1.73
8.05
1.55
2.11
1.23
1.42
2.33
1.51
1.57
1.17
1.69
3.46
1.58
0.88
5.70
1.07
1.46
2.16
1.14
1.32
1.24
7.79
1.85
1.90
1.19
1.26
3.07
1.51
1.03
1.05
1.42
2.28
1.70
1.07
1.05
1.09
1.13
0.89
1.19
1.69
1.69
2.65
2.02
0.87
1.36
1.15
0.76
1.35
1.49
1.44
2.80
2.02
1.11
1.50
1.97
1.24
1.29
1.34
1.21
1.62
1.21
1.52
1.45
1.57
1.58
1.45
2.59
1.49
1.63
1.73
3.80
1.32
1.38

5.0
370.1
1503.7
240.1
1806.8
296.9
598.1
1315.1
1014.4
3897.4
257.9
924.4
5.0
1272.9
5.0
94.3
173.2
923.1
1353.0
1300.2
566.0
172.5
141.6
4145.9
308.9
1072.1
5.0
485.5
667.1
376.5
5.0
5.0
1603.3
5.0
519.2
855.5
5.0
5.0
5.0
5.0
5.0
5.0
715.4
1281.5
1516.9
3887.8
1288.7
5.0
5.0
804.8
698.8
1906.7
1076.6
5.0
5.0
263.2
5.0
5.0
5.0
718.8
2171.8
5.0
5.0
5.0
4193.3
923.3
487.9
2900.6
473.1
572.3
5.0
2324.0
5.0
5.0

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Extended Data Table 2. Frequency of symptoms and comorbidities reported by participants
Participants
Symptom
(n=149)
%
Fever
125
83.9
Fatigue
106
71.1
Cough
93
62.4
Myalgia
92
61.7
Shortness of breath
66
44.3
Headache
63
42.3
Loss of smell/taste
50
33.3
Sore throat
38
25.3
Diarrhea
32
21.3
Presence of
comorbidities (HTN,
CAD, DM, COPD,
asthma, cancer)
16
10.7

528

HTN (hypertension), CAD (coronary artery disease), DM (diabetes mellitus), COPD (chronic obstructive pulmonary disease)

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

529

Extended Data Tables 3 and 4 are provided as separate Excel files.
Extended data table 5. Sequences of cloned recombinant antibodies
Antibody ID

530
531

C002
C003
C004
C005
C006
C008
C009
C010
C013
C016
C017
C018
C019
C021
C022
C027
C029
C030
C031
C101
C102
C103
C104
C105
C106
C107
C108
C109
C110
C111
C112
C113
C114
C115
C116
C117
C118
C119
C120
C121
C122
C123
C124
C125
C126
C127
C128
C130
C131
C132
C133
C134
C135
C138
C139
C140
C141
C143
C144
C145
C146
C147
C148
C150
C151
C153
C154
C155
C156
C164
C165
C201
C202
C204
C205
C207
C208
C209
C210
C211
C212
C214
C215
C216

IGH VDJ (nt)

IGH VDJ (aa)

IGL VJ (nt)

IGL VJ (aa)

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTATCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAGD
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRS
GCCATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAG
AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGS
CAGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGACCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTTACTAGCTCTGC
QVQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSE
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTGACTACTG
QVQLVESGGGLVKPGGSLRLSCAASGFIFSDYCMSWIRRAPGKGLEWLSYISNSGTTRYYADSVKGRFTISRDNGRNSLYLQMDSLSAED
CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGACAGAGGGTCACCGTCTCTTGTTCTGG
QSVLTQPPSASGTPGQRVTVSCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFS
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVISYDGRNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRANQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGS
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCATGGCTTCTGGATACACCTTCACCGGCTACT
QVQLVQSGAEVKKPGASVKVSCMASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLR
CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGG
QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRF
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPAKGLEWVAVILYDGSGKYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATG
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDT
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGATATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GCCATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAG
AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGS
GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGC
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRA
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAIHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCGTCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSIRSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGTTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRS
TCCTATGAGCTGACACAGCCACCCTCAGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGA
SYELTQPPSVSVAPGKTARITCGENNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSN
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTG
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGG
DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPD
CAGGTGCAGTTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCGTCACTTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTA
QVQLQESGPGLVKPSETLSVTCTVSGGSISSSRYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGCGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDSVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSG
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTG
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGG
DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPD
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACG
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGD
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYAASSLQSGVPSRFSGS
CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACT
QVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDT
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACT
QVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGGTCACTCAGTGGTTTCT
QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFYWTWIRQPPGKGLEWIGETNHFGSTGYKPSLKSRVTISVDMSRNQFSLKVTSVTAADT
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQTVTANYLAWYQQKPGQAPRLLIYGASKRATGIPDRFSGS
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCTCCTGCGCTGTCTATGGTGGGTCCCTCAGTGGTTACT
QVQLQQWGAGLLKPSETLSLSCAVYGGSLSGYYWSWIRQPPGKGLEWIGEINHFGSTGYNPSLKSRVTISVDTSKSQFSVKLSSVTAADT
GAAATTGTGTTGACGCAGTCTCCAGGCACCGTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCTGG
EIVLTQSPGTVSLSPGERATLSCWASQSVSASYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACT
QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAED
CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGG
QSALTQPPSASGSPGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRF
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGCCTCCGTCAGCAGTGGT
QLQLQESGPGLVKPSETLSLTCTVSGASVSSGSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
TCCTATGAGCTGACACAGCCACCCTCAGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGG
SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYFDSDRPSGIPERFSGSN
CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGG
QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISAYNGNTNFAQKLQGRVTMTTDTSTSTAYMELRSLRS
CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGG
QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSG
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTACT
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTNWWSWVRQPPGKGLEWIGEIYHTGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAAD
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTG
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISGDNAKNSLYLHMNSLRA
CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGG
QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVTKRPSGVPDRF
CAGGTACAGCTGCAGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTG
QVQLQQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYMQWSSLKASD
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRASQSISYWLAWYQQKPGKAPKLLIYQASSLESGVPSRFSGS
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACT
QLQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAV
CAGTCTGTGCTGACGCAGCCACCCTCGGTGTCTGAAGCCCCCAGGCAGAGGGTCACCATCTCCTGTTCTGG
QSVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQVPGKAPKLLIYYDDLLPSGVSDRFSG
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCCATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSHAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACCGG
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAACTTTG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRASQSMSSWLAWYQQKPGNAPKLLIYKASSLESGVPSRFSGS
CAGGTGCAGCTGGTGGAGTCTGGAGGAGGGTTGATCCAGCCTGGGGGGTCCCTGAAACTCTCCTGTGTAGTCTCTGGGTTCACCGTCAGTAAGAACTA
QVQLVESGGGLIQPGGSLKLSCVVSGFTVSKNYISWVRQAPGKGLEWVSVIFAGGSTFYADSVKGRFAISRDNSNNTLFLQMNSLRVEDT
CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACTGG
QSVLTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYQQLPGRAPKVLISGNNIRPSEVPDRFS
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGATAAAGCCAGGGCGGTCCCTGAGACTCTCTTGTACAGCCTCTGGATTCACCTTTGGTGATTATGC
QVQLVESGGGLIKPGRSLRLSCTASGFTFGDYAMTWFRQAPGKGLEWVGFIRSKAYGGTTGYAASVKYRFTISRDDSKSIAYLQMDSLKT
GATATTGTGATGACTCAGTCTCCACTCTCCCTGTCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGG
DIVMTQSPLSLSVTPGEPASISCRSSQSLLHSNGNNYFDWYLQKPGQSPQLLIYLGSNRASGVPD
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTACAGTACCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTYSTYAMHWVRQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGC
NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSG
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGEGLEWVAVISYDGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRA
CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGG
QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNLVSWYQQLPGTAPKLLIYENNKRPSGIPDRFSG
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
CAGCCTGTGCTGACTCAATCGCCCTCTGCCTCTGCCTCCCTGGGAGCCTCGGTCAAGCTCACCTGCACTCT
QPVLTQSPSASASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLNTDGSHSKGDGIPD
CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKLQGRVTMTRDTSTSTVYMELSSLRS
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGGYKYVSWYQRHPGKAPKLMIYDVSNRPSGVSNRF
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSLIYPGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAED
GCCATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACACAGTCACCATCACTTGCCAG
AIRMTQSPSSLSASVGDTVTITCQASQDISKYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWISPVSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRS
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFS
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGCTCACCGTCAGTAGCAAC
EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVLYSGGSSFYADSVKGRFTISRDNSKNTLYLQMNSLRAED
GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGGTCACCGTCAGTAGGAAC
EVQLVESGGGLIQPGGSLRLSCAASGVTVSRNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAED
GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGGCTATA
EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYSMNWVRQAPGKGPEWVSYISRSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDE
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPATLSLSPGERATLSCRASQSFSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG
CAGGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGACCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTTACTAGCTCTGC
QVQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSE
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCTCCTGCGCTGTCTCTGGTGGCTCCATCGGTAGTTACT
QVQLQESGPGLVKPSETLSLSCAVSGGSIGSYFWSWIRQPPGKGLEWIGYLHYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTA
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGC
NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVINEDNQRPSGVPDRFS
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLR
CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGG
QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSG
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCACCTATG
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSTITGSGRDTYYADSVKGRFTISRDNSKNTLFLQLNSLRAED
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVNSRQLAWYQQKPGQAPRLLIYGASSRATGIPERFSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAACTACT
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSGGSTGYAQKFQGRVTMTRDTSTSTVYMELSSLRS
TCCTATGAGCTGACACAGCCACCCTCAGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGG
SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSN
CAGGTGCAGCTGGTGCAGTCTGGGTCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATG
QVQLVQSGSEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWMGRIIPILALANYAQKFQGRVTITADKSTSTAYMELSSLRSED
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTAAT
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSNNWWSCVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAAD
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVILYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAACTATGC
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAISGSDGSTYYAGSVKGRFTISRDNSKNTLYLQMNSLRAE
TCCTATGAGCTGACACAGCCACCCTCAGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGG
SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSN
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTACCTATTG
EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYWMSWVRQPPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRA
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGC
NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYSADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAG
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGS
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAGTCACCGTCAGTAGCAAC
EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSLIYSGGSTFYADSVKGRFTISRDNSENTLYLQMNTLRAED
GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATG
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMFWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGC
NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGTGTCAGCACCAAG
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKYMTWVRQAPGKGLEWVSVLYSGGSDYYADSVKGRFTISRDNSKNALYLQMNSLRVE
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSNDVGSYTLVSWYQQYPGKAPKLLIFEGTKRSSGISNRFSG
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAACAACT
EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNRLRAED
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCAGCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFSVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAED
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGACTCACCTTCACTGCCTATA
EVQLVESGGGLVKPGGSLRLSCAASGLTFTAYRMNWVRQAPGKGLEWLSSISNTNGDIYYADSVKGRFTISRDNAKNSLYLQMNSLRAD
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDIGVYNYISWSQQHPGKAPKVMIYDVTNRPSGVSNRFSG
GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGATTTACCAACTACTG
EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASD
CAGGCTGTGGTGACCCAGGAGCCCTCACTGACTGTGTCCCCAGGAGGGACAGTCACTCTCACCTGTGGCTC
QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKSGQAPRTLIYETSIKHSWTPARFS
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCAGAGACTCTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAATT
EVQLVESGGGLVQPGGSQRLSCAASGFTVSSNYMSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKGRFTISRDNSKNTLYLQMNSLRPED
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVMTQSPATLSVSPGERATLSCRASQSVSSHLAWYQQKPGQAPRLLIYGASTRATGIPTRFSGS
GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGTAGCCTCTGGATTCACCTTCAGTAGCTACT
EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYWMHWVRQVPGKGPVWVSHINSEGSSTNYADSVRGRFTISRDNAKDTLYLQMNNLRA
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGYYNFVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFS
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATA
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSCISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAE
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGC
NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSG
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGYSTYYVDSVKGRFTISRDNSKNTLYLQMNSLRAED
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFS
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCGCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVMSYDGSSKYYADSVKGRFTISRDNSKNTLCLQMNSLR
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAG
DIQMTQSPSSLSASVGDRVTITCQASQGISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGS
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCATCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATAIPARFSGS
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTTCCTGTGGGGG
SYELTQPPSVSVAPGQTARISCGGNNIGSKNVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGS
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAGTGTCAGCACCAAG
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKYMTWVRQAPGKGLEWVSVLYSGGSDYYADSVKGRFTISRDNSKNALYLQMNSLRVE
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA
QSALTQPASVSGSPGQSITISCTGTSNDVGSYTLVSWYQQYPGKAPKLLIFEVTKRSSGISNRFSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCGTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGTAGCTATG
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGRIIPIVGIANYAQKFQGRVTITADKSSSTAYMELSSLRSEDT
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS
GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGC
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRA
CATCCGGATGACCCAGTCTCCATCTTCTGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGC
IRMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYVESSLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTAAGACTCTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACT
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAED
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAG
DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSG
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGAACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTTAGCACCTATGC
EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSAISGSGAGTFYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGACACACCTTCACCAGCTACT
QVQLVQSGAEVKKPGASVKVSCKASGHTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRS
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATG
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG
GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTG
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLKWSSLKASDS
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVLTQSPGTLSLSPGERATLSCRASQSVSGSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSG
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGTCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGA
QVQLVQSGAEVKKSGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMXLSSLXS
TCCTATGAGCTGACACAGCCACCCTCGGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTACCTGTGGGGG
SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGHAPVLVVYDDSDRPSGIPERFSGS
GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACT
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTFSRDNSKNTLYLQMNSLRAED
GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGAATTCACCGTCAGTAGCAACT
EVQLVESGGGLVQPGGSLRLSCAASEFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRPED
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGS
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCGTCACCGGCTATT
QVQLVQSGAEVKKPGASVKVSCKASGYTVTGYYIHWVRQAPGQGLEWMGWISPNSGGTNYAQKFQGWVTMTRDMSITTAYMELSRLRS
CTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGT
LTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEDSKRPSGVSNRFSGSK
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATG
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAAIWYDGSNKHYADSVKGRFTISRDNSKNTLYLQMNSLRA
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISSYLTWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATG
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAITDSGDGTFYADSVKGRFTISRDNSKNTLYLQMNSLRAE
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTACG
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGD
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGG
DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSG

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

532

Extended Data Table 6. Effective and inhibitory concentrations of the monoclonal antibodies
SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 RBD
Participant ID
Antibody ID
IC50 ng/ml
IC80 ng/ml
IC90 ng/ml
EC50 ng/ml
COV21
C002
8.88
21.95
37.61
3.14
COV21
C003
313.79
992.62
>1000
6.37
COV21
C004
10.67
41.08
91.71
2.39
COV21
C005
60.49
130.65
205.20
4.41
COV21
C006
321.51
>1000
>1000
1.81
COV21
C008
625.46
>1000
>1000
4.63
COV21
C009
4.82
14.54
29.34
1.80
COV21
C010
>1000
>1000
>1000
5.44
COV21
C013
42.48
360.59
>1000
2.59
COV21
C016
>1000
>1000
>1000
7.41
COV21
C017
72.67
256.18
543.87
1.63
COV21
C018
>1000
>1000
>1000
1.53
COV21
C019
>1000
>1000
>1000
11.85
COV21
C021
>1000
>1000
>1000
1.25
COV21
C022
73.57
314.71
736.87
2.40
COV21
C027
>1000
>1000
>1000
2.65
COV21
C029
>1000
>1000
>1000
4.13
COV21
C030
>1000
>1000
>1000
2.89
COV21
C031
>1000
>1000
>1000
22.69
COV107
C101
8.20
30.15
65.30
1.51
COV107
C102
34.03
84.21
143.23
4.54
COV107
C103
4.38
12.58
23.59
3.77
COV107
C104
23.31
72.12
140.28
8.31
COV107
C105
26.09
72.24
133.70
5.20
COV107
C106
>1000
>1000
>1000
19.03
COV107
C107
>1000
>1000
>1000
11.55
COV107
C108
480.69
>1000
>1000
5.32
COV107
C110
18.44
45.11
77.28
7.29
COV107
C112
111.79
701.99
>1000
3.38
COV107
C113
>1000
>1000
>1000
6.93
COV107
C114
>1000
>1000
>1000
9.51
COV107
C115
198.33
958.18
>1000
3.40
COV107
C116
>1000
>1000
>1000
37.56
COV107
C117
348.00
>1000
>1000
5.38
COV107
C118
103.69
417.76
>1000
3.45
COV107
C119
9.12
39.45
97.78
3.57
COV107
C120
13.26
26.73
40.30
1.41
COV107
C121
6.73
14.31
22.33
2.85
COV107
C122
22.80
57.77
100.12
2.67
COV107
C123
149.22
355.47
595.51
1.92
COV107
C124
341.82
937.26
>1000
2.23
COV107
C125
43.32
92.54
144.26
1.87
COV107
C126
>1000
>1000
>1000
4.78
COV107
C127
68.74
190.96
347.31
2.62
COV072
C128
101.22
263.35
460.73
1.95
COV072
C130
>1000
>1000
>1000
2.05
COV072
C131
30.52
178.90
759.11
1.67
COV072
C132
708.67
>1000
>1000
2.92
COV072
C133
>1000
>1000
>1000
1.98
COV072
C134
>1000
>1000
>1000
1.57
COV072
C135
16.61
32.81
48.90
1.80
COV072
C136
>1000
>1000
>1000
33.61
COV072
C137
>1000
>1000
>1000
25.22
COV072
C138
>1000
>1000
>1000
2.94
COV072
C139
>1000
>1000
>1000
1.89
COV072
C140
23.88
66.24
120.69
2.19
COV072
C141
>1000
>1000
>1000
1.71
COV047
C143
>1000
>1000
>1000
3.66
COV047
C144
6.91
17.28
29.66
3.24
COV047
C145
3.04
14.51
36.79
3.86
COV047
C146
>1000
>1000
>1000
>1000
COV047
C147
>1000
>1000
>1000
>1000
COV047
C148
>1000
>1000
>1000
64.69
COV047
C150
>1000
>1000
>1000
8.11
COV047
C151
31.79
363.97
>1000
4.30
COV047
C153
70.71
490.08
>1000
3.17
COV047
C154
435.50
>1000
>1000
2.92
COV047
C155
11.00
35.75
77.01
3.30
COV047
C156
>1000
>1000
>1000
3.32
COV047
C164
239.15
865.40
>1000
2.06
COV072
C165
40.81
138.66
297.38
4.25
COV96
C201
>1000
>1000
>1000
2.98
COV96
C202
>1000
>1000
>1000
3.40
COV96
C204
>1000
>1000
>1000
3.73
COV96
C205
>1000
>1000
>1000
>1000
COV96
C207
158.52
960.39
>1000
1.87
COV96
C208
>1000
>1000
>1000
>1000
COV96
C209
>1000
>1000
>1000
3.79
COV96
C210
50.73
155.24
298.90
2.83
COV96
C211
12.79
34.87
62.89
2.82
COV96
C212
>1000
>1000
>1000
>1000
COV96
C214
>1000
>1000
>1000
5.75
COV96
C215
>1000
>1000
>1000
5.33
COV96
C216
>1000
>1000
>1000
9.53

SARS-CoV RBD
EC50 ng/ml
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
5.99
696.05
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
106.75
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
3.817
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
10.65
>1000
>1000
>1000
>1000
>1000
>1000
9.41
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
17.944
>1000

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

533

Extended Data Figures

534
535

Extended Data Figure 1. Clinical correlates. a, Age distribution (Y axis) for all males and

536

females in the cohort p=0.2074. b, Duration of symptoms in days (Y axis) for all males and females

537

in the cohort p=0.8704. c, Time between symptom onset and plasma collection (Y axis) for all

538

males and females in the cohort p=0.5514. d, Subjective symptom severity on a scale of 0-10 (Y

539

axis) for all males and females in the cohort p=0.1888. e, Age distribution (Y axis) for all cases

540

and contacts in the cohort p=0.0305. f, Duration of symptoms in days (Y axis) for all cases and

541

contacts in the cohort p=0.1241. g, Time between symptom onset and plasma collection in days

542

(Y axis) for all cases and contacts in the cohort p=0.1589. h, Symptom severity (Y axis) for all

543

cases and contacts in the cohort p=0.0550. i, Age distribution (Y axis) for all outpatient and

544

hospitalized participants p=0.0024. j, Duration of symptoms in days (Y axis) for all outpatient and

545

hospitalized participants in the cohort p=<0.0001. k, Time between symptom onset and plasma

546

collection in days (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0001.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

547

l, Symptom severity (Y axis) for all outpatient and hospitalized participants in the cohort

548

p=<0.0001. Horizontal bars indicate median values. Statistical significance was determined using

549

two-tailed Mann-Whitney U test.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

550
551

Extended Data Figure 2. Clinical correlates of plasma antibody titers. a, AUC for IgG anti-

552

RBD (Y axis) for all cases and contacts in the cohort p=0.0107. b, AUC for IgM anti-RBD (Y

553

axis) for all cases and contacts in the cohort p=0.5371. c, AUC for IgG anti-S (Y axis) for all cases

554

and contacts in the cohort p=0.0135. d, AUC for IgM anti-S (Y axis) for all cases and contacts in

555

the cohort p=0.7838. e, AUC for IgM anti-RBD (Y axis) for all males and females in the cohort

556

p=0.9597. f, AUC for IgG anti-S (Y axis) for all males and females in the cohort p=0.0275. g,

557

AUC for IgM anti-S (Y axis) for all males and females in the cohort p=0.5363. h, AUC for IgM

558

anti-RBD (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0059. i, AUC

559

for IgG anti-S (Y axis) for all outpatient and hospitalized participants in the cohort p=0.0623. j,

560

AUC for IgM anti-S (Y axis) for all outpatient and hospitalized participants in the cohort p=0.2976.

561

Horizontal bars indicate median values. Statistical significance was determined using two-tailed

562

Mann-Whitney U test.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

563
564

Extended Data Figure 3. Additional clinical correlates of plasma antibody titers. a, Time

565

between symptom onset and plasma collection in days (X axis) plotted against AUC for IgG anti-

566

RBD (Y axis) r=-0.0261 p=0.7533. b, Time between symptom onset and plasma collection in days

567

(X axis) plotted against AUC for IgG anti-S (Y axis) r=-0.1495 p=0.0697. c, Time between

568

symptom onset and plasma collection in days (X axis) plotted against AUC for IgM anti-S (Y axis)

569

r=0.1496 p=0.0695. d, Age (X axis) plotted against AUC for IgM anti-RBD (Y axis) r=0.0172

570

p=0.8355. e, Age (X axis) plotted against AUC for IgG anti-S (Y axis) r=0.1523 p=0.0638. f, Age

571

(X axis) plotted against AUC for IgM anti-S (Y axis) r=0.0565 p=0.4934. g, Duration of symptoms

572

in days (X axis) plotted against AUC for IgG anti-RBD (Y axis) r=0.1525, p=0.0633. h, Duration

573

of symptoms in days (X axis) plotted against AUC for IgM anti-RBD (Y axis) r=-0.3187,

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

574

p=<0.0001. i, Duration of symptoms in days (X axis) plotted against AUC for IgG anti-S (Y axis)

575

r=0.0329, p=0.6904. j, Duration of symptoms in days (X axis) plotted against AUC for IgM anti-

576

S (Y axis) r=0.0824, p=0.3177. k, Severity of symptoms (X axis) plotted against AUC for IgG

577

anti-RBD (Y axis) r=0.2679 p=0.0010. l, Severity of symptoms (X axis) plotted against AUC for

578

IgM anti-RBD (Y axis) r=-0.1943 p=0.0176. m, Severity of symptoms (X axis) plotted against

579

AUC for IgG anti-S (Y axis) r=0.1187 p=0.1492. n, Severity of symptoms (X axis) plotted against

580

AUC for IgM anti-S (Y axis) r=0.1597 p=0.0517. All correlations were analyzed by two-tailed

581

Spearman’s.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

582
583

Extended Data Figure 4. Diagrammatic representation of the SARS-CoV2 pseudovirus

584

luciferase assay. a, Co-transfection of pNL4-3ΔEnv-nanoluc and pSARS-CoV-2 spike vectors

585

into 293T cells leads to production of SARS-CoV-2 Spike-pseudotyped HIV-1 particles (SARS-

586

CoV-2 pseudovirus) carrying the Nanoluc gene. b, SARS-CoV-2 pseudovirus is incubated for 1 h

587

at 37°C with plasma or monoclonal antibody dilutions. The virus-antibody mixture is used to infect

588

ACE2-expressing 293T cells, which will express nanoluc Luciferase upon infection. c, Relative

589

luminescence units (RLU) reads from lysates of ACE2-expressing 293T cells infected with

590

increasing amounts of SARS-CoV-2 pseudovirus.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

591
592

Extended Data Figure 5. Clinical correlates of neutralization. a, Anti-RBD IgM AUC (X axis)

593

plotted against NT50 (Y axis) r=0.3119, p=0.0001. b, Anti-S IgM AUC (X axis) plotted against

594

NT50 (Y axis) r=0.3211, p=<0.0001. c, Duration of symptoms in days (X axis) plotted against NT50

595

(Y axis) r=0.1997, p=0.0146. d, Time between symptom onset and plasma collection in days (X

596

axis) plotted against NT50 (Y axis) r=-0.1344, p=0.1033. e, Symptom severity (X axis) plotted

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

597

against NT50 (Y axis) r=0.2234, p=0.0062. f, Age (X axis) plotted against NT50 (Y axis) r=0.3005,

598

p=0.0002. All correlations were analyzed by two-tailed Spearman’s. Dotted line (NT50=5)

599

represents lower limit of detection (LLOD) of pseudovirus neutralization assay. Samples with

600

undetectable neutralizing titers were plotted at LLOD.

601

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

602
603

Extended Data Figure 6. Flow cytometry. Gating strategy used for cell sorting. Gating was on

604

singlets that were CD20+ and CD3-CD8-CD16-Ova-. Sorted cells were RBD-PE+ and RBD-

605

AF647+.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

606
607

Extended Data Figure 7. Frequency distributions of human V genes. The two-tailed t test with

608

unequal variance was used to compare the frequency distributions of human V genes of anti-

609

SARS-CoV-2 antibodies from this study to Sequence Read Archive SRP01097034.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

610
611

Extended Data Figure 8. Analysis of antibody somatic hypermutation and CDR3 length. a,

612

For each individual, the number of somatic nucleotide mutations (Y axis) at the IGVH and IGVL

613

are shown on the left panel, and the amino acid length of the CDR3s (Y axis) are shown on the

614

right panel. The horizontal bar indicated the mean. b, same as in a but for all antibodies combined.

615

c, Distribution of the hydrophobicity GRAVY scores at the IGH CDR3 in antibody sequences

616

from this study compared to a public database (see Methods).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

617
618

Extended Data Figure 9. Binding of the monoclonal antibodies to the RBD of SARS-CoV-2

619

and SARS-CoV. a, EC50 values for binding to the RBD of SARS-CoV-2. b and c, Binding curves

620

and EC50 values for binding to the RBD of SARS-CoV.

621

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

622
623

Extended Data Figure 10. Biolayer interferometry experiment. showing binding of antibodies

624

C144, C101, C002, C121, C009, C019 (see also main text Fig. 4). Graphs show secondary

625

antibody binding to preformed C121 IgG-RBD complexes. The table displays the shift in

626

nanometers after second antibody (Ab2) binding to the antigen in the presence of the first antibody

627

(Ab1). Values are normalized by the subtraction of the autologous antibody control.

628

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

629

References

630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for
controlling emerging coronaviruses. Nat Rev Microbiol 11, 836-848,
doi:10.1038/nrmicro3143 (2013).
Gralinski, L. E. & Baric, R. S. Molecular pathology of emerging coronavirus infections. J
Pathol 235, 185-195, doi:10.1002/path.4454 (2015).
Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280 e278,
doi:10.1016/j.cell.2020.02.052 (2020).
Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein. Cell 181, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).
Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other
Human Coronaviruses. Trends Immunol, doi:10.1016/j.it.2020.03.007 (2020).
Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B
cells in HIV-infected individuals. Nature 458, 636-640, doi:10.1038/nature07930 (2009).
Tiller, T. et al. Autoreactivity in human IgG+ memory B cells. Immunity 26, 205-213,
doi:10.1016/j.immuni.2007.01.009 (2007).
Murugan, R. et al. Clonal selection drives protective memory B cell responses in
controlled human malaria infection. Sci Immunol 3, doi:10.1126/sciimmunol.aap8029
(2018).
Briney, B., Inderbitzin, A., Joyce, C. & Burton, D. R. Commonality despite exceptional
diversity in the baseline human antibody repertoire. Nature 566, 393-397,
doi:10.1038/s41586-019-0879-y (2019).
ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus:
synergy and coverage of escape mutants. PLoS Med 3, e237,
doi:10.1371/journal.pmed.0030237 (2006).
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of
SARS-CoV-2 and SARS-CoV. Science 368, 630-633, doi:10.1126/science.abb7269
(2020).
Walls, A. C. et al. Unexpected Receptor Functional Mimicry Elucidates Activation of
Coronavirus Fusion. Cell 176, 1026-1039 e1015, doi:10.1016/j.cell.2018.12.028 (2019).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
antibody. Nature, doi:10.1038/s41586-020-2349-y (2020).
Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human
monoclonal antibodies. Proc Natl Acad Sci U S A 104, 12123-12128,
doi:10.1073/pnas.0701000104 (2007).
Salazar, G., Zhang, N., Fu, T. M. & An, Z. Antibody therapies for the prevention and
treatment of viral infections. NPJ Vaccines 2, 19, doi:10.1038/s41541-017-0019-3
(2017).
Bournazos, S. & Ravetch, J. V. Anti-retroviral antibody FcgammaR-mediated effector
functions. Immunol Rev 275, 285-295, doi:10.1111/imr.12482 (2017).
Feinberg, M. B. & Ahmed, R. Advancing dengue vaccine development. Science 358,
865-866, doi:10.1126/science.aaq0215 (2017).
Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in
COVID-19. Nat Rev Immunol, doi:10.1038/s41577-020-0321-6 (2020).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Van Rompay, K. K. A. et al. A combination of two human monoclonal antibodies limits
fetal damage by Zika virus in macaques. Proc Natl Acad Sci U S A 117, 7981-7989,
doi:10.1073/pnas.2000414117 (2020).
Plotkin, S. A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 17,
1055-1065, doi:10.1128/CVI.00131-10 (2010).
Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV
antibodies that mimic CD4 binding. Science 333, 1633-1637,
doi:10.1126/science.1207227 (2011).
Robbiani, D. F. et al. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in
Brazil and Mexico. Cell 169, 597-609 e511, doi:10.1016/j.cell.2017.04.024 (2017).
Ehrhardt, S. A. et al. Polyclonal and convergent antibody response to Ebola virus vaccine
rVSV-ZEBOV. Nat Med 25, 1589-1600, doi:10.1038/s41591-019-0602-4 (2019).
Pappas, L. et al. Rapid development of broadly influenza neutralizing antibodies through
redundant mutations. Nature 516, 418-422, doi:10.1038/nature13764 (2014).
Kane, M. et al. Identification of Interferon-Stimulated Genes with Antiretroviral Activity.
Cell Host Microbe 20, 392-405, doi:10.1016/j.chom.2016.08.005 (2016).
Adachi, A. et al. Production of acquired immunodeficiency syndrome-associated
retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J
Virol 59, 284-291 (1986).
Wang, Z. et al. Isolation of single HIV-1 Envelope specific B cells and antibody cloning
from immunized rhesus macaques. J Immunol Methods 478, 112734,
doi:10.1016/j.jim.2019.112734 (2020).
Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells
by single cell RT-PCR and expression vector cloning. J Immunol Methods 329, 112-124,
doi:10.1016/j.jim.2007.09.017 (2008).
von Boehmer, L. et al. Sequencing and cloning of antigen-specific antibodies from
mouse memory B cells. Nat Protoc 11, 1908-1923, doi:10.1038/nprot.2016.102 (2016).
Klein, F. et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that
target virus escape variants. J Exp Med 211, 2361-2372, doi:10.1084/jem.20141050
(2014).
Schoofs, T. et al. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of
the HIV Envelope. Immunity 50, 1513-1529 e1519, doi:10.1016/j.immuni.2019.04.014
(2019).
Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable
domain sequence analysis tool. Nucleic Acids Res 41, W34-40, doi:10.1093/nar/gkt382
(2013).
Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin
repertoire sequencing data. Bioinformatics 31, 3356-3358,
doi:10.1093/bioinformatics/btv359 (2015).
Rubelt, F. et al. Onset of immune senescence defined by unbiased pyrosequencing of
human immunoglobulin mRNA repertoires. PLoS One 7, e49774,
doi:10.1371/journal.pone.0049774 (2012).
Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character of a
protein. J Mol Biol 157, 105-132, doi:10.1016/0022-2836(82)90515-0 (1982).
Guy, H. R. Amino acid side-chain partition energies and distribution of residues in
soluble proteins. Biophys J 47, 61-70, doi:10.1016/S0006-3495(85)83877-7 (1985).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092619; this version posted May 22, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

720
721
722
723
724
725
726
727
728
729

37
38
39
40

DeWitt, W. S. et al. A Public Database of Memory and Naive B-Cell Receptor
Sequences. PLoS One 11, e0160853, doi:10.1371/journal.pone.0160853 (2016).
Mastronarde, D. N. Automated electron microscope tomography using robust prediction
of specimen movements. J Struct Biol 152, 36-51, doi:10.1016/j.jsb.2005.07.007 (2005).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for
rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290-296,
doi:10.1038/nmeth.4169 (2017).
Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF
Chimera. J Struct Biol 157, 281-287, doi:10.1016/j.jsb.2006.06.010 (2007).

